A machine learning-based radiomics model for prediction of tumor mutation burden in gastric cancer

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy

(2023) Xiao-Peng Duan et al.   Frontiers in Oncology

Radiomics Model for Predicting TP53 Status Using CT and Machine Learning Approach in Laryngeal Squamous Cell Carcinoma

(2022) Ruxian Tian et al.   Frontiers in Oncology

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

(2022) Keun-Wook Lee et al.   CLINICAL CANCER RESEARCH

A multiphase contrast-enhanced CT radiomics model for prediction of human epidermal growth factor receptor 2 status in advanced gastric cancer

(2022) Tingting Ma et al.   Frontiers in Genetics

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

(2021) D.J. McGrail et al.   ANNALS OF ONCOLOGY

Radiomic machine learning for predicting prognostic biomarkers and molecular subtypes of breast cancer using tumor heterogeneity and angiogenesis properties on MRI

(2021) Ji Young Lee et al.   EUROPEAN RADIOLOGY

Application of artificial intelligence-driven endoscopic screening and diagnosis of gastric cancer

(2021) Yu-Jer Hsiao et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole‐slide images

(2020) Akira Ono et al.   Cancer Medicine

Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients

(2020) Lan Song et al.   Frontiers in Oncology

A CT-based Radiomics Model for Prediction of Lymph Node Metastasis in Early Stage Gastric Cancer

(2020) Xujie Gao et al.   ACADEMIC RADIOLOGY

Impact of high tumor mutational burden in solid tumors and challenges for biomarker application

(2020) Mairéad G. McNamara et al.   CANCER TREATMENT REVIEWS

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

(2019) Saori Mishima et al.   Journal for ImmunoTherapy of Cancer

Artificial intelligence in cancer imaging: Clinical challenges and applications

(2019) Wenya Linda Bi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers

(2019) S Trebeschi et al.   ANNALS OF ONCOLOGY

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

(2019) F Wang et al.   ANNALS OF ONCOLOGY

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

(2019) Martin Reck et al.   EUROPEAN JOURNAL OF CANCER

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives

(2018) Julien Taieb et al.   CANCER TREATMENT REVIEWS

Repeatability and reproducibility of radiomic features: A systematic review

(2018) Alberto Traverso et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

(2018) Seung Tae Kim et al.   NATURE MEDICINE

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes

(2018) Simona De Rosa et al.   Cancers

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

(2018) T A Chan et al.   ANNALS OF ONCOLOGY

CT-based radiomics signature for differentiating Borrmann type IV gastric cancer from primary gastric lymphoma

(2017) Zelan Ma et al.   EUROPEAN JOURNAL OF RADIOLOGY

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Tumour heterogeneity and resistance to cancer therapies

(2017) Ibiayi Dagogo-Jack et al.   Nature Reviews Clinical Oncology

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor neoantigens: building a framework for personalized cancer immunotherapy

(2015) Matthew M. Gubin et al.   JOURNAL OF CLINICAL INVESTIGATION

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach

(2014) Hugo J. W. L. Aerts et al.   Nature Communications